Kintara Therapeutics

Receive alerts
Market Cap:
$28.7 m
0.88 USD
52 weeks high
52 weeks low

In brief

Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).

Kintara's REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.


  • Kintara announces $15M common stock and warrants offering priced at premium to market
  • Kintara Therapeutics enrolls patients at 26 sites within around 7 months

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Kintara has two promising oncology drug candidates with strong safety profiles in late-stage trials

CEO Saiid Zarrabian said the GBM AGILE trial speeds up “Phase 3 development, while reducing costs” giving Kintara “three separate shots on goal unique to VAL-083”

on 3/8/21